MASTL has been proposed as a novel therapeutic target in different tumor contexts; more interestingly, its inhibition sensitizes squamous cancer cells to cisplatin [96], colon cancer cells to 5-fluorouracil [105], and lung and breast cancer cells to radiation therapy [106,107]. Here, MASTL is linked to breast cancer.